FY2025 · ended Dec 31, 2025 · Revenue $789,000 · Filed Mar 12, 2026
Seres Therapeutics, Inc. (MCRB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $789,000 and net income of $5.7 million. Free cash flow was $865,000. As of Sep 30, 2026 it held $17.5 million in cash and investments and $35.8 million in total debt.
Revenue (TTM)
$2.12M
Net income (TTM)
$-46.95M
-970.5% vs year-ago TTM
Operating cash flow (TTM)
$-63.94M
-177.3% vs year-ago TTM
Free cash flow (TTM)
$-63.97M
-173.8% vs year-ago TTM
EPS (TTM)
$-4.87
-886.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.59M
-94.5% vs prior year
Net cash
$-18.24M
as of Sep 30, 2026
Operating margin
-3656.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MCRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1609809
- Former names
- Seres Therapeutics, Inc. (until Nov 4, 2026); Seres Health, Inc. (until May 14, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $789,000 | — | $0 | $7.1M | $144.9M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M | -$65.6M |
| Diluted EPS | $0.64 | $0.00 | -$17.77 | -$2.31 | — |
| Operating cash flow | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M |
| Stockholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M |
| Cash and investments | $45.8M | $30.8M | $128.0M | $181.3M | $291.2M |
| Total debt | $83.0M | $91.6M | $207.2M | $161.5M | $48.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 26, 2026 | Oct 22, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Aug 4, 2026 | Jul 31, 2026 |
All 724 Seres Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.